IHT is an attractive candidate to develop as an anti-cancer drug due to its decrease in expression of Bcl-2, Mcl-1, XIAP, and Survivin in NCI-H460 tumorspheroids and its downregulation of Mcl-1 and Survivin in A549 with siNR4A1 to activate the intrinsic apoptosis pathway (Figure 5). Here, BCL2 is linked to cancer.